Stock Research for ORMP

ORMP

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ORMP Stock Chart & Research Data

The ORMP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ORMP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ORMP Due diligence Resources & Stock Charts

The ORMP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ORMP Detailed Price Forecast - CNN Money CNN View ORMP Detailed Summary - Google Finance
Yahoo View ORMP Detailed Summary - Yahoo! Finance Zacks View ORMP Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ORMP Trends & Analysis - Trade-Ideas Barrons View ORMP Major Holders - Barrons
NASDAQ View ORMP Call Transcripts - NASDAQ Seeking View ORMP Breaking News & Analysis - Seeking Alpha
Spotlight View ORMP Annual Report - CompanySpotlight.com OTC Report View ORMP OTC Short Report - OTCShortReport.com
TradeKing View ORMP Fundamentals - TradeKing Charts View ORMP SEC Filings - Bar Chart
WSJ View Historical Prices for ORMP - The WSJ Morningstar View Performance/Total Return for ORMP - Morningstar
MarketWatch View the Analyst Estimates for ORMP - MarketWatch CNBC View the Earnings History for ORMP - CNBC
StockMarketWatch View the ORMP Earnings - StockMarketWatch MacroAxis View ORMP Buy or Sell Recommendations - MacroAxis
Bullish View the ORMP Bullish Patterns - American Bulls Short Pains View ORMP Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ORMP Stock Mentions - StockTwits PennyStocks View ORMP Stock Mentions - PennyStockTweets
Twitter View ORMP Stock Mentions - Twitter Invest Hub View ORMP Investment Forum News - Investor Hub
Yahoo View ORMP Stock Mentions - Yahoo! Message Board Seeking Alpha View ORMP Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ORMP - SECform4.com Insider Cow View Insider Transactions for ORMP - Insider Cow
CNBC View ORMP Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ORMP - OTC Markets
Yahoo View Insider Transactions for ORMP - Yahoo! Finance NASDAQ View Institutional Holdings for ORMP - NASDAQ


Stock Charts

FinViz View ORMP Stock Insight & Charts - FinViz.com StockCharts View ORMP Investment Charts - StockCharts.com
BarChart View ORMP Stock Overview & Charts - BarChart Trading View View ORMP User Generated Charts - Trading View




Latest Financial News for ORMP


Oramed to Present at Cardiometabolic Health Congress
Posted on Tuesday October 23, 2018

Now in its 13th year, the Cardiometabolic Health Congress is the largest, US-based, multidisciplinary conference focused solely on the management of cardiometabolic risk and the prevention of cardiovascular and metabolic disease. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center.


Oramed Enrolls First Patient in Its Clinical Study for Oral Insulin in the Treatment of NASH
Posted on Thursday October 04, 2018

NEW YORK, Oct. 4, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has enrolled the first patient in an exploratory clinical study of its oral insulin capsule, ORMD-0801, in the treatment of nonalcoholic steatohepatitis (NASH). The three-month treatment study, recently approved by Israel's Ministry of Health, will assess the effectiveness of ORMD-0801 in reducing liver fat content, inflammation and fibrosis in patients with NASH. Data from preclinical studies and clinical studies of ORMD-0801 demonstrate Oramed's oral insulin capsule has the potential to reduce inflammation of the liver.


Is Oramed Pharmaceuticals Inc’s (NASDAQ:ORMP) Balance Sheet Strong Enough To Weather A Storm?
Posted on Thursday September 20, 2018

The direct benefit for Oramed Pharmaceuticals Inc (NASDAQ:ORMP), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-offRead More...


Oramed Receives FDA Clearance for IND Application for Its Oral GLP-1 Analog Capsule
Posted on Monday September 17, 2018

NEW YORK, Sept. 17, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for human trials of its oral GLP-1 analog capsule ORMD-0901. In a prior Phase 1 study on type 2 diabetic patients, Oramed's ORMD-0901 capsule was well tolerated and showed encouraging efficacy, including reducing blood sugar levels following a standard meal as compared to a placebo. Oramed's planned Phase 1 pharmacokinetic (PK) study is a fully-randomized, single-blind, placebo-controlled 4-way crossover study which will evaluate safety in addition to the pharmacokinetics of ORMD-0901 compared to placebo and to open label Byetta®, a GLP-1 analog currently on the market, in up to 15 healthy subjects.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.